Home Cart Sign in  
Chemical Structure| 80418-24-2 Chemical Structure| 80418-24-2

Structure of Notoginsenoside R1
CAS No.: 80418-24-2

Chemical Structure| 80418-24-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Notoginsenoside R1, the main bioactive component isolated and purified from the roots of Panax notoginseng (Burk.)F.H.Chen, is reported to have some neuronal protective, antihypertensive effects.

Synonyms: Sanchinoside R1; Sanqi glucoside R1; NG-R1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Notoginsenoside R1

CAS No. :80418-24-2
Formula : C47H80O18
M.W : 933.13
SMILES Code : C[C@]([C@@](C[C@H]1O)([H])[C@@]2(C)CC[C@@H]3O)(C[C@@H]([C@]2(C3(C)C)[H])O[C@@](O[C@@H]([C@H]([C@@H]4O)O)CO)([H])[C@@H]4O[C@@](OC[C@H]([C@@H]5O)O)([H])[C@@H]5O)[C@@]6(C)[C@]1([C@]([C@@](CC/C=C(C)/C)(C)O[C@H](O[C@@H]7CO)[C@H](O)[C@H]([C@@H]7O)O)([H])CC6)[H]
Synonyms :
Sanchinoside R1; Sanqi glucoside R1; NG-R1
MDL No. :MFCD00210535
InChI Key :LLPWNQMSUYAGQI-OOSPGMBYSA-N
Pubchem ID :441934

Safety of Notoginsenoside R1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
3D intestinal organoid model 100 μM 4 days Increased Lgr5+ cells and budding rates PMC11192909
NCM460 human intestinal epithelial cells 100 μM 24 hours Promoted wound healing and reduced cell apoptosis PMC11192909
MDA-MB-231 cells 75-150 mmol/L 24 hours Inhibited proliferation, migration, and invasion in MDA-MB-231 cells PMC7929486
Adult primary cardiomyocytes 100 μmol/L NGR1 reduced H2O2-induced apoptosis in adult primary cardiomyocytes, enhanced cell viability, and reduced mitochondrial ROS accumulation. PMC9287735
Primary cardiomyocytes 100 μmol/L NGR1 protected primary cardiomyocytes from H2O2 and OGD-induced oxidative stress injury and reduced apoptosis. PMC9287735
H9C2 cells 100 μmol/L 30 minutes NGR1 protected H9C2 cells from H2O2-induced oxidative stress injury, reduced apoptosis, decreased ROS levels, increased SOD activity, and reduced mitochondrial ROS accumulation and oxidative DNA damage. PMC9287735
U87 cells 100 μM and 200 μM 24 hours To evaluate the effect of NGR1 on U87 cell viability, results showed that NGR1 significantly inhibited U87 cell viability. PMC11300025
LN18 cells 100 μM and 200 μM 24 hours To evaluate the effect of NGR1 on LN18 cell viability, results showed that NGR1 significantly inhibited LN18 cell viability. PMC11300025
Bone marrow mesenchymal stem cells (MSCs) 0.1 µM, 1 µM, 10 µM, 100 µM 24 hours, 48 hours, 72 hours Promoted MSC proliferation and protected MSCs against H2O2-induced apoptosis PMC11558819
Murine neonatal cardiomyocytes (CMs) 25 μM 24 hours To evaluate the protective effect of NG-R1 on hypoxia/reoxygenation-induced apoptosis. Results showed that NG-R1 significantly inhibited apoptosis, reduced LDH release, and improved cell viability. PMC10310839
MCF-7 cells 148.9 mmol/L 24 hours Inhibited proliferation, migration, invasion, and angiogenesis, and promoted cell cycle arrest and apoptosis in MCF-7 cells PMC7929486

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57/BL6 mice Myocardial ischemia/reperfusion injury model Intraperitoneal injection 25 mg/kg Every 2 hours for a total of 3 times, starting 30 minutes before ischemic surgery To evaluate the protective effect of NG-R1 on myocardial ischemia/reperfusion injury. Results showed that NG-R1 significantly reduced myocardial infarction area, alleviated myocardial cell damage, and improved cardiac function. PMC10310839
C57BL/6 mice Myocardial infarction model Caudal vein injection 267 ng/kg MSN-NGR1 Single dose MSN-NGR1-CD11b antibody nanoparticles improved cardiac function after myocardial infarction by enhancing the activation of AKT and MAPK signaling pathways and the nuclear translocation of YAP, reducing infarct size and collagen deposition, promoting angiogenesis, and regulating macrophage phenotype and inflammatory factors. PMC9287735
C57BL/6 mice DSS-induced colitis model Oral 25, 50, 125 mg/kg/d Once per day for 10 days Dose-dependently ameliorated mucosal inflammation and enhanced epithelial repair evidenced by increased tight junction proteins, mucus production and reduced permeability in colitis mice PMC11192909

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02975076 Stroke, Acute ... More >> Ischemic Attack, Transient Less << Not Applicable Not yet recruiting November 2019 -
NCT02316730 Healthy Phase 1 Completed - China, Sichuan ... More >> West China Second University Hospital Chengdu, Sichuan, China, 610000 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.07mL

0.21mL

0.11mL

5.36mL

1.07mL

0.54mL

10.72mL

2.14mL

1.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories